Search

Your search keyword '"Shaw, Bronwen"' showing total 1,193 results
Start Over Author "Shaw, Bronwen"
1,193 results on '"Shaw, Bronwen"'

2. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis.

Author

Taylor, Mallory, Cole, Steve, Strom, Joelle, Brazauskas, Ruta, Baker, K, Phelan, Rachel, Buchbinder, David, Hamilton, Betty, Schoemans, Hélène, Shaw, Bronwen, Sharma, Akshay, Bhatt, Neel, Badawy, Sherif, Preussler, Jaime, Mayo, Samantha, Jamani, Kareem, Nishihori, Taiga, Lee, Michelle, Knight, Jennifer, and Winestone, Lena

Subjects
Humans, Female, Middle Aged, Male, Transcriptome, Hematopoietic Stem Cell Transplantation, Cross-Sectional Studies, Gene Expression Profiling, Surveys and Questionnaires
Abstract

Patient-reported outcomes (PROs) capture subjective social determinants of health (SDOHs), which can affect health outcomes through the stress response pathway. The conserved transcriptional response to adversity (CTRA) is a stress-mediated proinflammatory transcriptomic pattern that has been linked to adverse hematopoietic cell transplant (HCT) outcomes. This study examined the association of pretransplant CTRA with patient-reported SDOHs in allogeneic HCT recipients. In this cross-sectional study, pre-HCT SDOH-related PROs included the 36-Item Short Form Health Survey and the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). CTRA was assessed by RNA sequencing of whole blood specimens, with mixed effects linear regression models relating CTRA expression to PRO scores while controlling for age, sex, race, disease, and performance status. Among 121 patients, the median age was 54 years, 42% were female, and 91% were White. CTRA was elevated in participants reporting lower scores on the FACT-BMT (P = .003), including the general (P = .003) and BMT-specific (P = .014) components. Effects were driven by the social well-being domain (P = .0001). This corresponded to an 8% to 15% difference in CTRA RNA expression across a 4 standard deviation range in patient-reported SDOHs. Ancillary bioinformatics analyses confirmed the association of well-being with reduced proinflammatory transcription pathway activity [cyclic AMP response element-binding protein, (CREB), NF-κB, and activating protein-1 (AP-1)]. In conclusion, HCT-treated patients who experience unfavorable social conditions show elevated CTRA expression in pretransplant blood samples. These data highlight the biologic sequelae of social well-being and community context and suggest a potential molecular mechanism for the impact of social gradients in HCT outcomes. Targeting this pathway could optimize outcomes in this high-risk population.

Published
2023

3. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

Author

Chhabra, Saurabh, Jerkins, James H., Monahan, Kathleen, Szabo, Aniko, Shah, Nirav N., Abedin, Sameem, Runaas, Lyndsey, Fenske, Timothy S., Pasquini, Marcelo C., Shaw, Bronwen E., Drobyski, William R., Saber, Wael, D’Souza, Anita, Dhakal, Binod, Mohan, Meera, Longo, Walter, and Hamadani, Mehdi

Published
2024
Full Text
View/download PDF

4. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

Author

Shaw, Bronwen, Jimenez-Jimenez, Antonio, Burns, Linda, Logan, Brent, Khimani, Farhad, Shaffer, Brian, Shah, Nirav, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy, Choe, Hannah, Ambinder, Richard, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen, Howard, Alan, Luznik, Leo, Norkin, Maxim, Pidala, Joseph, Ratanatharathorn, Voravit, Confer, Dennis, Devine, Steven, Horowitz, Mary, Bolaños-Meade, Javier, and Komanduri, Krishna

Subjects
HLA, Hematopoietic cell transplant, Mismatched unrelated donor, Post transplant cyclophosphamide, Humans, Bone Marrow, Follow-Up Studies, Prospective Studies, Cyclophosphamide, Graft vs Host Disease, Unrelated Donors, Recurrence
Abstract

The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year outcomes of the first multicenter prospective clinical trial using PTCy in the setting of mismatched unrelated donor (MMUD) bone marrow HCT. The study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity conditioning (RIC; n = 40), with the primary endpoint of 1-year overall survival (OS). The median follow-up for this study was 34 months (range, 12 to 46 months) in the RIC group and 36 months (range, 18 to 49 months) in the MAC group. Three-year OS and nonrelapse mortality were 70% and 15%, respectively, in the RIC group and 62% and 10% in the MAC group. No GVHD was reported after 1 year. The incidence of relapse was 29% in the RIC group and 51% in the MAC group. OS did not differ based on HLA match grade (63% in the 7/8 strata and 71% in the 4 to 6/8 strata). These encouraging outcomes, which were sustained for 3 years post-HCT, support the continued exploration of MMUD HCT using a PTCy platform. Important future areas to address include relapse reduction and furthering our understanding of optimal donor selection based on HLA and non-HLA factors.

Published
2023

5. Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

Author

Schonfeld, Sara J., Valcarcel, Bryan, Meyer, Christa L., Shaw, Bronwen E., Phelan, Rachel, Rizzo, J. Douglas, Brunson, Ann, Cooley, Julianne J. P., Abrahão, Renata, Wun, Ted, Gadalla, Shahinaz M., Engels, Eric, Albert, Paul S., Yusuf, Rafeek, Spellman, Stephen R., Curtis, Rochelle E., Auletta, Jeffery J., Muffly, Lori, Keegan, Theresa H. M., and Morton, Lindsay M.

Published
2024
Full Text
View/download PDF

8. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year

Author

Heslop, Helen E, Stadtmauer, Edward A, Levine, John E, Ballen, Karen K, Chen, Yi-Bin, DeZern, Amy E, Eapen, Mary, Hamadani, Mehdi, Hamilton, Betty K, Hari, Parameswaran, Jones, Richard J, Logan, Brent R, Kean, Leslie S, Leifer, Eric S, Locke, Frederick L, Maziarz, Richard T, Nemecek, Eneida R, Pasquini, Marcelo, Phelan, Rachel, Riches, Marcie L, Shaw, Bronwen E, Walters, Mark C, Foley, Amy, Devine, Steven M, and Horowitz, Mary M

Subjects
Stem Cell Research, Clinical Trials and Supportive Activities, Transplantation, Clinical Research, Bone Marrow Transplantation, Clinical Trials as Topic, Hematopoietic Stem Cell Transplantation, Humans, Transplants, BMT, Cell Therapy, Clinical Trial
Abstract

In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion, diversity, and access as cross-cutting themes were reviewed. This article summarizes the individual committee reports and their recommendations on the highest priority questions in hematopoietic stem cell transplant and cell therapy to address in multicenter trials.

Published
2021

9. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States

Author

Bhatt, Neel S, Brazauskas, Ruta, Salit, Rachel B, Syrjala, Karen, Bo-Subait, Stephanie, Tecca, Heather, Badawy, Sherif M, Baker, K Scott, Beitinjaneh, Amer, Bejanyan, Nelli, Byrne, Michael, Dias, Ajoy, Farhadfar, Nosha, Freytes, César O, Ganguly, Siddhartha, Hashmi, Shahrukh, Hayashi, Robert J, Hong, Sanghee, Inamoto, Yoshihiro, Jamani, Kareem, Kasow, Kimberly A, Khera, Nandita, Krem, Maxwell M, Lazarus, Hillard M, Lee, Catherine J, Lee, Stephanie, Majhail, Navneet S, Malone, Adriana K, Marks, David I, Mau, Lih-Wen, Mayo, Samantha J, Muffly, Lori S, Nathan, Sunita, Nishihori, Taiga, Page, Kristin M, Preussler, Jaime, Rangarajan, Hemalatha G, Rotz, Seth J, Salooja, Nina, Savani, Bipin N, Schears, Raquel, Schechter-Finkelstein, Tal, Schiller, Gary, Shah, Ami J, Sharma, Akshay, Wang, Trent, Wirk, Baldeep, Battiwalla, Minoo, Schoemans, Hélène, Hamilton, Betty, Buchbinder, David, Phelan, Rachel, and Shaw, Bronwen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Transplantation, Clinical Research, Rehabilitation, Behavioral and Social Science, Quality Education, Female, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Return to Work, Survivors, Transplantation, Homologous, United States, Young Adult, Hematopoietic cell transplantation, Return to work, Quality of life, Young adult, Immunology, Cardiovascular medicine and haematology
Abstract

Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted this study to assess the post-HCT work status of survivors of allogeneic HCT who underwent HCT as YAs and to analyze the patient-, disease-, and HCT-related factors associated with their work status at 1 year post-HCT. Using Center for International Blood and Marrow Transplant Research data, we evaluated the post-HCT work status (full-time, part-time work, unemployed, or medical disability) of 1365 YA HCT survivors who underwent HCT between 2008 and 2015. Percentages of work status categories were reported at 4 time points: 6 months, 1 year, 2 years, and 3 years post-HCT. Percentages of post-HCT work status categories at the 1-year time point were also described in relation to survivors' pre-HCT work status categories. Factors associated with 1-year post-HCT work status (full-time or part-time work) were examined using logistic regression. From 6 months to 3 years post-HCT, the percentage of survivors working full-time increased from 18.3% to 50.7% and the percentage working part-time increased from 6.9% to 10.5%. Of patients in full-time work pre-HCT, 50% were unemployed or on medical disability at 1 year post-HCT. Female sex (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.40 to 0.77), HCT Comorbidity Index score ≥3 (OR, 0.57; 95% CI, 0.39 to 0.82), pre-HCT unemployment (OR, 0.37; 95% CI, 0.24 to 0.56), medical disability (OR, 0.44; 95% CI, 0.28 to 0.70), development of grade III-IV acute graft-versus-host disease (OR, 0.52; 95% CI, 0.34 to 0.80), and relapse within 1 year post-HCT (OR, 0.34; 95% CI, 0.21 to 0.56) were associated with a lower likelihood of employment at 1 year post-HCT. Compared with myeloablative conditioning (MAC) with total body irradiation (TBI), MAC without TBI (OR, 1.71; 95% CI, 1.16 to 2.53) was associated with a greater likelihood of employment at 1 year post-HCT. Graduate school-level education (OR, 2.47; 95% CI, 1.49 to 4.10) was also associated with a greater likelihood of employment at 1 year post-HCT. Although the work status among YA HCT survivors continued to improve over time, a substantial subset became or remained unemployed or on medical disability. These findings underscore the need for effective interventions to support return to work in this population.

Published
2021

10. Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Author

Mayor, Neema P, Wang, Tao, Lee, Stephanie J, Kuxhausen, Michelle, Vierra-Green, Cynthia, Barker, Dominic J, Auletta, Jeffrey, Bhatt, Vijaya R, Gadalla, Shahinaz M, Gragert, Loren, Inamoto, Yoshihiro, Morris, Gerald P, Paczesny, Sophie, Reshef, Ran, Ringdén, Olle, Shaw, Bronwen E, Shaw, Peter, Spellman, Stephen R, and Marsh, Steven GE

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Hematology, 2.1 Biological and endogenous factors, Aetiology, Adolescent, Adult, Child, Child, Preschool, Female, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Infant, Infant, Newborn, Male, Transplantation Conditioning, Unrelated Donors, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeUltrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hematopoietic cell transplantation, improving survival and reducing post-transplant complications. However, most studies included relatively small numbers of patients. Here we report the findings from a large, multicenter validation study.MethodsUHR HLA typing was available on 5,140 conventionally 10 out of 10 HLA-matched patients with malignant disease transplanted between 2008 and 2017.ResultsAfter UHR HLA typing, 82% of pairs remained 10 out of 10 UHR-matched; 12.3% of patients were 12 out of 12 UHR HLA-matched. Compared with 12 out of 12 UHR-matched patients, probabilities of grade 2-4 acute graft-versus-host disease (aGVHD) were significantly increased with UHR mismatches (overall P = .0019) and in those patients who were HLA-DPB1 T-cell epitope permissively mismatched or nonpermissively mismatched (overall P = .0011). In the T-cell-depleted subset, the degree of UHR HLA mismatch was only associated with increased transplant-related mortality (TRM) (overall P = .0068). In the T-cell-replete subset, UHR HLA matching was associated with a lower probability of aGVHD (overall P = .0020); 12 out of 12 UHR matching was associated with reduced TRM risk when compared with HLA-DPB1 T-cell epitope permissively mismatched patients, whereas nonpermissive mismatching resulted in a greater risk (overall P = .0003).ConclusionThis study did not confirm that UHR 12 out of 12 HLA matching increases the probability of overall survival but does demonstrate that aGVHD risk, and in certain settings TRM, is lowest in UHR HLA-matched pairs and thus warrants consideration when multiple 10 out of 10 HLA-matched donors of equivalent age are available.

Published
2021

11. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Author

Shaw, Bronwen E, Jimenez-Jimenez, Antonio Martin, Burns, Linda J, Logan, Brent R, Khimani, Farhad, Shaffer, Brian C, Shah, Nirav N, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M, Choe, Hannah, Ambinder, Richard F, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R, Howard, Alan, Komanduri, Krishna V, Luznik, Leo, Norkin, Maxim, Pidala, Joseph A, Ratanatharathorn, Voravit, Confer, Dennis L, Devine, Steven M, Horowitz, Mary M, and Bolaños-Meade, Javier

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Transplantation, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Clinical Research, Regenerative Medicine, Good Health and Well Being, Adolescent, Adult, Aged, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphoma, Male, Medically Underserved Area, Middle Aged, Minority Groups, Myelodysplastic Syndromes, Prospective Studies, Registries, Transplantation Conditioning, Unrelated Donors, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeHematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.Patients and methodsWe performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.ResultsNotably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.ConclusionOur prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

Published
2021

13. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author

Hong, Sanghee, Brazauskas, Ruta, Hebert, Kyle M, Ganguly, Siddhartha, Abdel‐Azim, Hisham, Diaz, Miguel Angel, Beattie, Sara, Ciurea, Stefan O, Szwajcer, David, Badawy, Sherif M, Gratwohl, Alois A, LeMaistre, Charles, Aljurf, Mahmoud DSM, Olsson, Richard F, Bhatt, Neel S, Farhadfar, Nosha, Yared, Jean A, Yoshimi, Ayami, Seo, Sachiko, Gergis, Usama, Beitinjaneh, Amer M, Sharma, Akshay, Lazarus, Hillard, Law, Jason, Ulrickson, Matthew, Hashem, Hasan, Schoemans, Hélène, Cerny, Jan, Rizzieri, David, Savani, Bipin N, Kamble, Rammurti T, Shaw, Bronwen E, Khera, Nandita, Wood, William A, Hashmi, Shahrukh, Hahn, Theresa, Lee, Stephanie J, Rizzo, J Douglas, Majhail, Navneet S, and Saber, Wael

Subjects
Hematology, Cancer, Clinical Research, Prevention, Transplantation, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Community Health Planning, Female, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Public Health, Risk Factors, Transplantation, Homologous, Treatment Outcome, United States, Young Adult, allogeneic transplant, community health, hematopoietic cell transplantation, survival, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.

Published
2021

15. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.

Author

Buchbinder, David, Brazauskas, Ruta, Bo-Subait, Khalid, Ballen, Karen, Parsons, Susan, John, Tami, Hahn, Theresa, Sharma, Akshay, Steinberg, Amir, DSouza, Anita, Kumar, Anita, Yoshimi, Ayami, Wirk, Baldeep, Shaw, Bronwen, Freytes, César, LeMaistre, Charles, Bredeson, Christopher, Dandoy, Christopher, Almaguer, David, Marks, David, Szwajcer, David, Hale, Gregory, Schouten, Harry, Hashem, Hasan, Schoemans, Hélène, Murthy, Hemant, Lazarus, Hillard, Cerny, Jan, Tay, Jason, Yared, Jean, Adekola, Kehinde, Schultz, Kirk, Lehmann, Leslie, Burns, Linda, Aljurf, Mahmoud, Diaz, Miguel, Majhail, Navneet, Farhadfar, Nosha, Kamble, Rammurti, Olsson, Richard, Schears, Raquel, Seo, Sachiko, Beattie, Sara, Chhabra, Saurabh, Savani, Bipin, Badawy, Sherif, Ganguly, Siddhartha, Ciurea, Stefan, Marino, Susana, Gergis, Usama, Kuwatsuka, Yachiyo, Inamoto, Yoshihiro, Khera, Nandita, Hashmi, Shahrukh, Wood, William, and Saber, Wael

Subjects
Bone marrow transplantation, Lost to follow-up, Stem cell transplantation, Survivor, Adult, Aged, Child, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Survivors, Transplantation Conditioning, Transplantation, Homologous
Abstract

Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

Published
2020

16. Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry

Author

Cusatis, Rachel, Litovich, Carlos, Feng, Zhongyu, Allbee-Johnson, Mariam, Kapfhammer, Miranda, Mattila, Deborah, Akinola, Idayat, Phelan, Rachel, Broglie, Larisa, Auletta, Jeffery J., Steinert, Patricia, Bolon, Yung-Tsi, Akhtar, Othman, Bloomquist, Jenni, Chen, Min, Devine, Steven M., Bupp, Caitrin, Hamadani, Mehdi, Hengen, Mary, Jaglowski, Samantha, Kaur, Manmeet, Kuxhausen, Michelle, Lee, Stephanie J., Moskop, Amy, Page, Kristin M., Pasquini, Marcelo C., Rizzo, Doug, Saber, Wael, Spellman, Stephen R., Stefanski, Heather E., Tuschl, Eileen, Yusuf, Rafeek, Zhan, Keming, Flynn, Kathryn E., and Shaw, Bronwen E.

Published
2024
Full Text
View/download PDF

17. Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient Outcomes

Author

Bolon, Yung-Tsi, Atshan, Rasha, Allbee-Johnson, Mariam, Estrada-Merly, Noel, Auletta, Jeffery J., Broglie, Larisa, Cusatis, Rachel, Page, Kristin M., Phelan, Rachel, Sajulga, Ray, Jr., Shaw, Bronwen E., Spahn, Ashley, Steinert, Patricia, Stewart, Valerie, Vierra-Green, Cynthia, Lee, Stephanie J., and Spellman, Stephen R.

Published
2024
Full Text
View/download PDF

18. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Author

Al Malki, Monzr M., primary, Bo-Subait, Stephanie, additional, Logan, Brent, additional, Olson, Janelle, additional, Leckrone, Erin, additional, Wu, Juan, additional, Stefanski, Heather E., additional, Auletta, Jeffery J., additional, Spellman, Stephen R., additional, Malmberg, Craig, additional, Shaffer, Brian C., additional, Modi, Dipenkumar, additional, Khimani, Farhad, additional, Gooptu, Mahasweta, additional, Hamadani, Mehdi, additional, Broglie, Larisa, additional, Shaw, Bronwen E., additional, Devine, Steven Michael, additional, and Jimenez Jimenez, Antonio Martin, additional

Published
2024
Full Text
View/download PDF

20. Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020—Report from World Marrow Donor Association

Author

Jöris, Monique M., Schmidt, Alexander H., Bernas, Stefanie N., Feinberg, Jay, Sacchi, Nicoletta, Elmoazzen, Heidi, Fournier, Diane, Oguz, Fatma, Oliveira, Danielli, Yang, Kuo-Liang, Mousavi, Seied Asadullah, Moomivand, Soraya, Abecasis, Manuel, Villa, Juliana, Fechter, Mirjam M., Seval, Guldane Cengiz, Jeyarajah, Thaneya, Devine, Steven M., Shaw, Bronwen E., Galarza, Pablo, Malan, Richard, Harvey, Christopher, Forman, Stephen J., and Foeken, Lydia

Published
2022
Full Text
View/download PDF

21. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR

Author

Dehn, Jason, Spellman, Stephen, Hurley, Carolyn K, Shaw, Bronwen E, Barker, Juliet N, Burns, Linda J, Confer, Dennis L, Eapen, Mary, Fernandez-Vina, Marcelo, Hartzman, Robert, Maiers, Martin, Marino, Susana R, Mueller, Carlheinz, Perales, Miguel-Angel, Rajalingam, Raja, and Pidala, Joseph

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Hematology, Regenerative Medicine, Transplantation, Stem Cell Research, Prevention, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, 5.4 Surgery, Inflammatory and immune system, Adult, Cord Blood Stem Cell Transplantation, Donor Selection, Fetal Blood, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Infant, Newborn, Registries, Unrelated Donors, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Allogeneic hematopoietic cell transplantation involves consideration of both donor and recipient characteristics to guide the selection of a suitable graft. Sufficient high-resolution donor-recipient HLA match is of primary importance in transplantation with adult unrelated donors, using conventional graft-versus-host disease prophylaxis. In cord blood transplantation, optimal unit selection requires consideration of unit quality, cell dose and HLA-match. In this summary, the National Marrow Donor Program (NMDP) and the Center for International Blood and Marrow Transplant Research, jointly with the NMDP Histocompatibility Advisory Group, provide evidence-based guidelines for optimal selection of unrelated donors and cord blood units.

Published
2019

22. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.

Author

Pulsipher, Michael A, Logan, Brent R, Kiefer, Deidre M, Chitphakdithai, Pintip, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, Susan F, Varni, James W, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Ball, Edward D, Bolwell, Brian J, Bunin, Nancy J, Cheerva, Alexandra, Delgado, David C, Dvorak, Christopher C, Gillio, Alfred P, Hahn, Theresa E, Hale, Gregory A, Haight, Ann E, Hayes-Lattin, Brandon M, Kasow, Kimberly A, Linenberger, Michael, Magalhaes-Silverman, Margarida, Mori, Shahram, Prasad, Vinod K, Quigg, Troy C, Sahdev, Indira, Schriber, Jeffrey R, Shenoy, Shalini, Tse, William T, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Confer, Dennis L, Shaw, Bronwen E, and Switzer, Galen E

Subjects
Humans, Pain, Tissue and Organ Harvesting, Bone Marrow Transplantation, Transplantation, Homologous, Age Factors, Sex Factors, Time Factors, Adolescent, Tissue Donors, Female, Male, BM collection toxicities, Donor safety, PBSC collection toxicities, Stem cell transplantation, Transplantation, Chronic Pain, Neurosciences, Pediatric, Clinical Research, Stem Cell Research, Pain Research, Clinical Trials and Supportive Activities, Prevention, Immunology, Clinical Sciences
Abstract

Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels of pain, symptoms, and long-term recovery are lacking. To address this lack, we prospectively enrolled 294 donors age 20% of females and males age 13 to 17 years do not return to baseline pain levels by 1 year after BM donation. Studies aimed at decreasing symptoms and improving recovery in older children are warranted.

Published
2019

23. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Author

Pulsipher, Michael A, Logan, Brent R, Kiefer, Deidre M, Chitphakdithai, Pintip, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, O’Susan F, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Akard, Luke P, Artz, Andrew S, Ball, Edward D, Bayer, Ruthee-Lu, Bigelow, Carolyn, Bolwell, Brian J, Broun, E Randolph, Delgado, David C, Duckworth, Katharine, Dvorak, Christopher C, Hahn, Theresa E, Haight, Ann E, Hari, Parameswaran N, Hayes-Lattin, Brandon M, Jacobsohn, David A, Jakubowski, Ann A, Kasow, Kimberly A, Lazarus, Hillard M, Liesveld, Jane L, Linenberger, Michael, Litzow, Mark R, Longo, Walter, Magalhaes-Silverman, Margarida, McCarty, John M, McGuirk, Joseph P, Mori, Shahram, Parameswaran, Vinod, Prasad, Vinod K, Rowley, Scott D, Rybka, Witold B, Sahdev, Indira, Schriber, Jeffrey R, Selby, George B, Shaughnessy, Paul J, Shenoy, Shalini, Spitzer, Thomas, Tse, William T, Uberti, Joseph P, Vusirikala, Madhuri, Waller, Edmund K, Weisdorf, Daniel J, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Switzer, Galen E, Confer, Dennis L, and Shaw, Bronwen E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Patient Safety, Regenerative Medicine, Clinical Research, Neurosciences, Stem Cell Research - Nonembryonic - Human, Chronic Pain, Pain Research, Stem Cell Research, Adolescent, Adult, Female, Humans, Living Donors, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Peripheral Blood Stem Cells, Prospective Studies, Quality of Life, Unrelated Donors, Young Adult, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Unlike unrelated donor registries, transplant centers lack uniform approaches to related donor assessment and deferral. To test whether related donors are at increased risk for donation-related toxicities, we conducted a prospective observational trial of 11,942 related and unrelated donors aged 18-60 years. Bone marrow (BM) was collected at 37 transplant and 78 National Marrow Donor Program centers, and peripheral blood stem cells (PBSC) were collected at 42 transplant and 87 unrelated donor centers in North America. Possible presence of medical comorbidities was verified prior to donation, and standardized pain and toxicity measures were assessed pre-donation, peri-donation, and one year following. Multivariate analyses showed similar experiences for BM collection in related and unrelated donors; however, related stem cell donors had increased risk of moderate [odds ratios (ORs) 1.42; P

Published
2019

24. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Author

Pulsipher, Michael A, Logan, Brent R, Chitphakdithai, Pintip, Kiefer, Deidre M, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, Susan F, Varni, James W, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Akard, Luke P, Artz, Andrew S, Ball, Edward D, Bayer, Ruthee-Lu, Bigelow, Carolyn, Bolwell, Brian J, Broun, E Randolph, Bunin, Nancy J, Delgado, David C, Duckworth, Katharine, Dvorak, Christopher C, Hahn, Theresa E, Haight, Ann E, Hari, Parameswaran N, Hayes-Lattin, Brandon M, Jacobsohn, David A, Jakubowski, Ann A, Kasow, Kimberly A, Lazarus, Hillard M, Liesveld, Jane L, Linenberger, Michael, Litzow, Mark R, Longo, Walter, Magalhaes-Silverman, Margarida, McCarty, John M, McGuirk, Joseph P, Mori, Shahram, Prasad, Vinod K, Rowley, Scott D, Rybka, Witold B, Sahdev, Indira, Schriber, Jeffrey R, Selby, George B, Shaughnessy, Paul J, Shenoy, Shalini, Spitzer, Thomas, Tse, William T, Uberti, Joseph P, Vusirikala, Madhuri, Waller, Edmund K, Weisdorf, Daniel J, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Switzer, Galen E, Shaw, Bronwen E, and Confer, Dennis L

Subjects
Humans, Peripheral Blood Stem Cell Transplantation, Comorbidity, Adolescent, Adult, Aged, Middle Aged, Blood Donors, Female, Male, Young Adult, Peripheral Blood Stem Cells, BM collection toxicities, Donor safety, PBSC collection toxicities, Stem cell transplantation, Transplantation, Pain Research, Stem Cell Research - Nonembryonic - Human, Clinical Research, Chronic Pain, Stem Cell Research, Aging, Clinical Sciences, Immunology
Abstract

The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RDs) of peripheral blood stem cells (PBSCs). The effects of age on donation efficacy, toxicity, and long-term recovery in RDs are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms, and recovery in 1211 PBSC RDs aged 18 to 79 enrolled in the Related Donor Safety Study. RDs aged > 60 had a lower median CD34+ level before apheresis compared with younger RDs (age > 60, 59 × 106/L; age 41 to 60, 81 × 106/L; age 18 to 40, 121 × 106/L; P < .001). This resulted in older donors undergoing more apheresis procedures (49% versus 30% ≥ 2 collections, P < .001) and higher collection volumes (52% versus 32% > 24 L, P < .001), leading to high percentages of donors aged > 60 with postcollection thrombocytopenia

Published
2019

25. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation

Author

Duncan, Christine N, Brazauskas, Ruta, Huang, Jiaxing, Shaw, Bronwen E, Majhail, Navneet S, Savani, Bipin N, Flowers, Mary ED, Battiwalla, Minoo, Beebe, Kristen, Dietz, Andrew C, Dvorak, Christopher C, Giller, Roger, Jacobsohn, David A, Kletzel, Morris, Martin, Paul L, Nemecek, Eneida R, Nuechterlein, Brandon, Talano, Julie-An, Pulsipher, Michael A, and Baker, K Scott

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Hematology, Cancer, Prevention, Transplantation, Heart Disease, Obesity, Pediatric, Cardiovascular, Good Health and Well Being, Adolescent, Adult, Allografts, Cardiovascular Diseases, Child, Child, Preschool, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Male, Retrospective Studies, Risk Factors, Severity of Illness Index, Survival Rate, Oncology and Carcinogenesis, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24-230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0.6%), cardiomyopathy (3%), and cardiac-related death (0.5%). Patients who received anthracycline chemotherapy (HR 4.67, p = 0.036) or cranial or chest radiation (HR 5.58, p

Published
2018

26. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression

Author

Jacobsohn, David A, Loken, Michael R, Fei, Mingwei, Adams, Alexia, Brodersen, Lisa Eidenschink, Logan, Brent R, Ahn, Kwang Woo, Shaw, Bronwen E, Kletzel, Morris, Olszewski, Marie, Khan, Sana, Meshinchi, Soheil, Keating, Amy, Harris, Andrew, Teira, Pierre, Duerst, Reggie E, Margossian, Steven P, Martin, Paul L, Petrovic, Aleksandra, Dvorak, Christopher C, Nemecek, Eneida R, Boyer, Michael W, Chen, Allen R, Davis, Jeffrey H, Shenoy, Shalini, Savasan, Sureyya, Hudspeth, Michelle P, Adams, Roberta H, Lewis, Victor A, Kheradpour, Albert, Kasow, Kimberly A, Gillio, Alfred P, Haight, Ann E, Bhatia, Monica, Bambach, Barbara J, Haines, Hilary L, Quigg, Troy C, Greiner, Robert J, Talano, Julie-An M, Delgado, David C, Cheerva, Alexandra, Gowda, Madhu, Ahuja, Sanjay, Ozkaynak, Mehmet, Mitchell, David, Schultz, Kirk R, Fry, Terry J, Loeb, David M, and Pulsipher, Michael A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Pediatric, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Clinical Research, Transplantation, Pediatric Research Initiative, Hematology, Regenerative Medicine, Genetics, Stem Cell Research, Cancer, Pediatric Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Inflammatory and immune system, Adolescent, Adult, Allografts, Child, Child, Preschool, Disease-Free Survival, Female, Flow Cytometry, Hematopoietic Stem Cell Transplantation, Humans, Infant, Infant, Newborn, Leukemia, Myeloid, Acute, Male, Neoplasm, Residual, Transplantation Conditioning, Transplantation, Homologous, Unrelated Donors, WT1 Proteins, Cytogenetics and molecular genetics, Measurable residual disease, Stem cell transplantation, Laboratory hematology, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We enrolled 150 patients in a prospective multicenter study of children with acute myeloid leukemia undergoing hematopoietic stem cell transplantation (HSCT) to compare the detection of measurable residual disease (MRD) by a "difference from normal" flow cytometry (ΔN) approach with assessment of Wilms tumor 1 (WT1) gene expression without access to the diagnostic specimen. Prospective analysis of the specimens using this approach showed that 23% of patients screened for HSCT had detectable residual disease by ΔN (.04% to 53%). Of those patients who proceeded to transplant as being in morphologic remission, 10 had detectable disease (.04% to 14%) by ΔN. The disease-free survival of this group was 10% (0 to 35%) compared with 55% (46% to 64%, P < .001) for those without disease. The ΔN assay was validated using the post-HSCT specimen by sorting abnormal or suspicious cells to confirm recipient or donor origin by chimerism studies. All 15 patients who had confirmation of tumor detection relapsed, whereas the 2 patients with suspicious phenotype cells lacking this confirmation did not. The phenotype of the relapse specimen was then used retrospectively to assess the pre-HSCT specimen, allowing identification of additional samples with low levels of MRD involvement that were previously undetected. Quantitative assessment of WT1 gene expression was not predictive of relapse or other outcomes in either pre- or post-transplant specimens. MRD detected by ΔN was highly specific, but did not identify most relapsing patients. The application of the assay was limited by poor quality among one-third of the specimens and lack of a diagnostic phenotype for comparison.

Published
2018

27. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues

Author

Worel, Nina, Aljurf, Mahmoud, Anthias, Chloe, Buser, Andreas S, Cody, Meghann, Fechter, Mirjam, Galeano, Sebastian, Greinix, Hildegard T, Kisch, Annika M, Koh, Mickey B C, Mengling, Thilo, Nicoloso, Grazia, Niederwieser, Dietger, Pulsipher, Michael A, Seber, Adriana, Shaw, Bronwen E, Stefanski, Heather E, Switzer, Galen E, Szer, Jeff, van Walraven, Suzanna M, Yang, Hung, and Halter, Jörg P

Published
2022
Full Text
View/download PDF

30. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Author

Fuchs, Ephraim J., McCurdy, Shannon R., Solomon, Scott R., Wang, Tao, Herr, Megan R., Modi, Dipenkumar, Grunwald, Michael R., Nishihori, Taiga, Kuxhausen, Michelle, Fingerson, Stephanie, McKallor, Caroline, Bashey, Asad, Kasamon, Yvette L., Bolon, Yung-Tsi, Saad, Ayman, McGuirk, Joseph, Paczesny, Sophie, Gadalla, Shahinaz M., Marsh, Steven G.E., Shaw, Bronwen E., Spellman, Stephen R., Lee, Stephanie J., and Petersdorf, Effie W.

Published
2022
Full Text
View/download PDF

31. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018

Author

Valcarcel, Bryan, Schonfeld, Sara J., Meyer, Christa L., Brunson, Ann, Cooley, Julianne J.P., Abrahão, Renata, Wun, Ted, Auletta, Jeffery J., Gadalla, Shahinaz M., Engels, Eric, Albert, Paul S., Spellman, Stephen R., Rizzo, J. Douglas, Shaw, Bronwen E., Muffly, Lori, Keegan, Theresa H.M., and Morton, Lindsay M.

Published
2024
Full Text
View/download PDF

32. Social Determinants of Health, Disease, and Treatment Related Characteristics of Access Clinical Trial Participants

Author

Yusuf, Rafeek A., primary, Ndifon, Eric, additional, Silverman, Thomas, additional, Bankole, Lindsay, additional, Mattila, Deborah, additional, Olson, Janelle, additional, Kuxhausen, Michelle, additional, Bupp, Caitrin, additional, Devine, Steven M., additional, Auletta, Dr. Jeffery J., additional, Shaw, Bronwen E., additional, and Cusatis, Rachel, additional

Published
2024
Full Text
View/download PDF

33. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial

Author

Pidala, Joseph A., primary, Logan, Brent, additional, He, Naya, additional, Lee, Stephanie J, additional, Ciurea, Stefan O., additional, Devine, Steven M., additional, Shaw, Bronwen E., additional, Vogel, Jenny, additional, Erickson, Connor, additional, Bashey, Asad, additional, Doyle, Jerry, additional, DiFronzo, Nancy, additional, Farhadfar, Nosha, additional, Grunwald, Mike R., additional, Hayes-Lattin, Brandon, additional, Henderson, Lori, additional, Hogan, William J., additional, Horowitz, Mary M., additional, Leifer, Eric, additional, Symons, Heather, additional, Pusic, Dr. Iskra, additional, Srour, Samer A., additional, Arai, Sally, additional, Juckett, Mark, additional, Howard, Dianna S., additional, Uberti, Joseph, additional, Hill, LaQuisa Chimere, additional, Vasu, Sumithira, additional, and Dehn, Jason, additional

Published
2024
Full Text
View/download PDF

34. Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

Author

Schoettler, Michelle Long, primary, Bo-Subait, Stephanie, additional, Brazauskas, Ruta, additional, Abt, Peter L., additional, Hamilton, Betty K., additional, Levine, Matthew, additional, Orozco, Gabriel, additional, Porter, David L., additional, Savani, Bipin N., additional, Schoemans, Prof. Helene M., additional, Shaw, Bronwen E., additional, Sorror, Mohamed L., additional, Phelan, Rachel, additional, and Gupta, Meera, additional

Published
2024
Full Text
View/download PDF

35. Incorporating patient‐reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients

Author

Shaw, Bronwen E., primary, Flynn, Kathryn E., additional, He, Naya, additional, Cusatis, Rachel, additional, D'Souza, Anita, additional, Hamilton, Betty K., additional, Horowitz, Mary M., additional, Mattila, Deborah, additional, Phelan, Rachel, additional, Lee, Stephanie J., additional, and Brazauskas, Ruta, additional

Published
2024
Full Text
View/download PDF

36. Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy

Author

Kelly, Debra Lynch, Syrjala, Karen, Taylor, Mallory, Rentscher, Kelly E., Hashmi, Shahrukh, Wood, William A., Jim, Heather, Barata, Anna, Flynn, Kathryn E., Burns, Linda J., Shaw, Bronwen E., Petersdorf, Effie, Yero, Anela Carrazana, Emmrich, Amanda D., Morris, Keayra E., Costanzo, Erin S., and Knight, Jennifer M.

Published
2021
Full Text
View/download PDF

37. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic

Author

Hsu, Jack W., Farhadfar, Nosha, Murthy, Hemant, Logan, Brent R., Bo-Subait, Stephanie, Frey, Noelle, Goldstein, Steven C., Horowitz, Mary M., Lazarus, Hillard, Schwanke, Joshua D., Shah, Nirali N., Spellman, Stephen R., Switzer, Galen E., Devine, Steven M., Shaw, Bronwen E., and Wingard, John R.

Published
2021
Full Text
View/download PDF

40. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee

Author

Algwaiz, Ghada, Aljurf, Mahmoud, Koh, Mickey, Horowitz, Mary M., Ljungman, Per, Weisdorf, Daniel, Saber, Wael, Kodera, Yoshihisa, Szer, Jeff, Jawdat, Dunia, Wood, William A., Brazauskas, Ruta, Lehmann, Leslie, Pasquini, Marcelo C., Seber, Adriana, Lu, Pei Hua, Atsuta, Yoshiko, Riches, Marcie, Perales, Miguel-Angel, Worel, Nina, Okamoto, Shinichiro, Srivastava, Alok, Chemaly, Roy F., Cordonnier, Catherine, Dandoy, Christopher E., Wingard, John R., Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Majhail, Navneet S., Waghmare, Alpana A., Chao, Nelson, Kröger, Nicolaus, Shaw, Bronwen, Mohty, Mohamad, Niederwieser, Dietger, Greinix, Hildegard, and Hashmi, Shahrukh K.

Published
2020
Full Text
View/download PDF

41. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation

Author

Chhabra, Saurabh, Visotcky, Alexis, Pasquini, Marcelo C., Zhu, Fenlu, Tang, Xiaoying, Zhang, Mei-Jie, Thompson, Robert, Abedin, Sameem, D'Souza, Anita, Dhakal, Binod, Drobyski, William R., Fenske, Timothy S., Jerkins, James H., Douglas Rizzo, J., Runaas, Lyndsey, Saber, Wael, Shah, Nirav N., Shaw, Bronwen E., Horowitz, Mary M., Hari, Parameswaran N., and Hamadani, Mehdi

Published
2020
Full Text
View/download PDF

42. Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score

Author

Berro, Mariano, Chhabra, Saurabh, Piñana, José Luis, Arbelbide, Jorge, Rivas, Maria M., Basquiera, Ana Lisa, Vitriu, Adriana, Requejo, Alejandro, Milovic, Vera, Yantorno, Sebastian, Bentolila, Gonzalo, Garcia, Juan Jose, Castro, Martin, Palmer, Silvina, Saslavsky, Martin, Duarte, Patricio, Cerutti, Amalia, Jarchum, Gustavo, Tisi Baña, Matias, Thapa, Bicky, Solano, Carlos, Sureda, Anna, Rovira, Montserrat, Shaw, Bronwen E, and Kusminsky, Gustavo

Published
2020
Full Text
View/download PDF

44. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Author

D'Souza, Anita, Fretham, Caitrin, Lee, Stephanie J, Arora, Mukta, Brunner, Janet, Chhabra, Saurabh, Devine, Steven, Eapen, Mary, Hamadani, Mehdi, Hari, Parameswaran, Pasquini, Marcelo C, Perez, Waleska, Phelan, Rachel A, Riches, Marcie L, Rizzo, J Douglas, Saber, Wael, Shaw, Bronwen E, Spellman, Stephen R, Steinert, Patricia, Weisdorf, Daniel J, and Horowitz, Mary M

Published
2020
Full Text
View/download PDF

46. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors

Author

Hsu, Jack W., Shaw, Bronwen E., Kim, Soyoung, Logan, Brent R., Sees, Jennifer A., Confer, Dennis L., Pulsipher, Michael A., Shah, Nirali, Switzer, Galen E., Abidi, Muneer H., Ahmed, Ibrahim A., Anderlini, Paulo N., Bredeson, Christopher, Chhabra, Saurabh, Dandoy, Christopher E., Diaz, Miguel Angel, Farhadfar, Nosha, Ganguly, Siddhartha, Gergis, Usama, Hale, Gregory A., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberly A., Lazarus, Hillard M., Liesveld, Jane L., Murthy, Hemant S., Olsson, Richard F., Savani, Bipin N., Schears, Raquel, Seo, Sachiko, Solh, Melhern, Spitzer, Thomas, Steinberg, Amir, Sugrue, Michele, Warkentin, Phyllis, and Wingard, John R.

Published
2020
Full Text
View/download PDF

47. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Author

Kahn, Justine M., Brazauskas, Ruta, Tecca, Heather R., Bo-Subait, Stephanie, Buchbinder, David, Battiwala, Minoo, Flowers, Mary E.D., Savani, Bipin N., Phelan, Rachel, Broglie, Larisa, Abraham, Allistair A., Keating, Amy K., Daly, Andrew, Wirk, Baldeep, George, Biju, Alter, Blanche P., Ustun, Celalettin, Freytes, Cesar O., Beitinjaneh, Amer M., Duncan, Christine, Copelan, Edward, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Auletta, Jeffery J., Myers, Kasiani C., Williams, Kirsten M., Page, Kristin M., Vrooman, Lynda M., Norkin, Maxim, Byrne, Michael, Diaz, Miguel Angel, Kamani, Naynesh, Bhatt, Neel S., Rezvani, Andrew, Farhadfar, Nosha, Mehta, Parinda A., Hematti, Peiman, Shaw, Peter J., Kamble, Rammurti T., Schears, Raquel, Olsson, Richard F., Hayashi, Robert J., Gale, Robert Peter, Mayo, Samantha J., Chhabra, Saurabh, Rotz, Seth J., Badawy, Sherif M., Ganguly, Siddhartha, Pavletic, Steven, Nishihori, Taiga, Prestidge, Tim, Agrawal, Vaibhav, Hogan, William J., Inamoto, Yoshihiro, Shaw, Bronwen E., and Satwani, Prakash

Published
2020
Full Text
View/download PDF

48. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes

Author

Chhabra, Saurabh, Narra, Ravi K., Wu, Ruizhe, Szabo, Aniko, George, Gemlyn, Michaelis, Laura C., D'Souza, Anita, Dhakal, Binod, Drobyski, William R., Fenske, Timothy S., Jerkins, James H., Pasquini, Marcelo C., Rizzo, R. Douglas, Saber, Wael, Shah, Nirav N., Shaw, Bronwen E., Hamadani, Mehdi, and Hari, Parameswaran N.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results